Lobbied regarding intellectual property rights in trade agreements and international negotiations.
Saudi Arabia, Saudi Food and Drug Authority, lobbied Congress regarding pharmaceutical patent infringement issues. No bill, lobbied on patent troll issues regarding biopharmaceutical patents.
H.R. 1892, Bipartisan Budget Act, regarding all biopharmaceutical provisions.
H.R. 6157, the Department of Defense and Labor, Health and Human Services and Education Appropriations Act for Fiscal Year 2019 and Continuing Resolution, regarding all biopharmaceutical provisions. No bill, lobbied to raise awareness about Atrial Fibrillation and stroke prevention.
No bill, lobbied regarding biosimilars issues including naming, labeling and interchangeability.
H.R. 1245 and S. 469, Affordable and Safe Prescription Drug Importation Act, lobbied regarding all biopharmaceutical provisions.
H.R. 1703, Medical Product Communications Act of 2017, regarding all biopharmaceutical related provisions
H.R. 2851, Stop the Importation and Trafficking of Synthetic Analogues Act of 2017, regarding all biopharmaceutical related provisions
No bill, lobbied for changes to the 340B Drug Discount Program.
H.R. 4710, 340B PAUSE Act, lobbied regarding all biopharmaceutical provisions.
H.R. 4392, a bill to repeal the HOPPS final regulation related to changes in the payment amount for certain drugs under the 340B program, lobbied regarding all biopharmaceutical provisions.
H.R. 2026, the Pharmaceutical Information Exchange (PIE) Act of 2017, lobbied regarding all biopharmaceutical provisions.
S. 2312, Helping Ensure Low-Income Patients have Access to Care and Treatment (HELP) Act, regarding all biopharmaceutical related provisions.
S.2453, Ensuring the Value of the 340B Program Act of 2018, regarding all biopharmaceutical related provisions.
H.R. 5598 340B Optimization Act, regarding all biopharmaceutical related provisions.
H.R. 6071 SERV Communities Act, regarding all biopharmaceutical related provisions.
H.R. 6240, Drug Discount Accountability Act, regarding all biopharmaceutical related provisions.
H.R. 6143, S. 2554, Patient Right to Know Drug Prices Act, regarding all biopharmaceutical related provisions.
H.R. 6, SUPPORT for Patients and Communities Act, regarding all biopharmaceutical related provisions. H.R. 1, Tax Cuts and Jobs Act, regarding all pharmaceutical related provisions. H.R. 849, S. 260, S. 251 Protecting Seniors Access to Medicare Act, lobbied regarding all biopharmaceutical related provisions.
S.771, Improving Access To Affordable Prescription Drugs Act, lobbied regarding all biopharmaceutical related provisions. 
S.348, Prescription Drug and Health Improvement Act of 2017, lobbied regarding all biopharmaceutical related provisions.
S.637, Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017, lobbied regarding all biopharmaceutical related provisions.
No bill, American Patients First Prescription Drug Blueprint, regarding all biopharmaceutical related provisions.
H.R. 6505, Medicare Negotiation and Competitive Licensing Act of 2018, regarding all biopharmaceutical related provisions.
H.R. 6642, to amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs, regarding all biopharmaceutical related provisions.
S. 2553, H.R. 6144, Know the Lowest Price Act of 2018, regarding all biopharmaceutical related provisions. American Health Care Act, regarding all biopharmaceutical related provisions.
Continuing Budget Resolution, lobbied regarding all biopharmaceutical provisions.
Better Care Reconciliation Act, regarding all biopharmaceutical related provisions.
S. 1771, Department of Labor, HHS and Education Appropriations Act, regarding all pharmaceutical related provisions.
H.R. 1625, Consolidates Appropriations Act, regarding all pharmaceutical related provisions.
TRD - Trade (domestic/foreign) CPT - Copyright/Patent/Trademark HCR - Health Issues TAX - Taxation/Internal Revenue Code MMM - Medicare/Medicaid BUD - Budget/Appropriations
24 - Commerce, Dept of (DOC) 34 - Health & Human Services, Dept of (HHS) 137 - Health Resources & Services Administration (HRSA) 2 - HOUSE OF REPRESENTATIVES 1 - SENATE 22 - U.S. Trade Representative (USTR) 24 - Commerce, Dept of (DOC) 34 - Health & Human Services, Dept of (HHS) 137 - Health Resources & Services Administration (HRSA) 2 - HOUSE OF REPRESENTATIVES 1 - SENATE 22 - U.S. Trade Representative (USTR) 24 - Commerce, Dept of (DOC) 34 - Health & Human Services, Dept of (HHS) 137 - Health Resources & Services Administration (HRSA) 2 - HOUSE OF REPRESENTATIVES 1 - SENATE 22 - U.S. Trade Representative (USTR) 24 - Commerce, Dept of (DOC) 34 - Health & Human Services, Dept of (HHS) 137 - Health Resources & Services Administration (HRSA) 2 - HOUSE OF REPRESENTATIVES 1 - SENATE 22 - U.S. Trade Representative (USTR) 24 - Commerce, Dept of (DOC) 34 - Health & Human Services, Dept of (HHS) 137 - Health Resources & Services Administration (HRSA) 2 - HOUSE OF REPRESENTATIVES 1 - SENATE 22 - U.S. Trade Representative (USTR) 24 - Commerce, Dept of (DOC) 34 - Health & Human Services, Dept of (HHS) 137 - Health Resources & Services Administration (HRSA) 2 - HOUSE OF REPRESENTATIVES 1 - SENATE 22 - U.S. Trade Representative (USTR)
BRISTOL-MYERS SQUIBB COMPANY
801 Pennsylvania Ave, NW, Suite 745, WASHINGTON, DC, 20004, US
PAUL ANTHONY WILLIAMS CHRISTOPHER PERNIE LANE PENRY PAUL ANTHONY WILLIAMS CHRISTOPHER PERNIE LANE PENRY PAUL ANTHONY WILLIAMS CHRISTOPHER PERNIE LANE PENRY PAUL ANTHONY WILLIAMS CHRISTOPHER PERNIE LANE PENRY PAUL ANTHONY WILLIAMS CHRISTOPHER PERNIE LANE PENRY PAUL ANTHONY WILLIAMS CHRISTOPHER PERNIE LANE PENRY